How to select the optimal GvHD prophylaxis regimen

The GvHD Hub are proud to present expert interviews directly from the 61st American Society of Hematology (ASH) meeting in Orlando, US. This interview with Arnon Nagler, Tel Aviv University, Tel Aviv, IL, was based on the question: How do you select the best graft-versus-host disease prophylaxis regimen?

Arnon Nagler explains the treatment landscape of GvHD prophylaxis. He describes the historical combination of cyclophosphamide and methotrexate for GvHD prevention. He also describes the big breakthrough of the anti-GvHD prophylaxis, post-transplant cyclophosphamide, that proved efficacious in the haploidentical setting, and also in the unrelated and sibling transplant setting. Arnon Nagler explains that shortly after transplant 50% of patients were able to discontinue immunosuppression when given post-transplant cyclophosphamide